한빛사논문
Si-Cho Kim 1,2†, Da-Won Kim 1,2†, Eun Ju Cho 3†, Jin-Young Lee 4, Jiwon Kim 5, Chaesun Kwon 5, Jeongsil Kim-Ha 5, Suk Kyun Hong 6, YoungRok Choi 6, Nam-Joon Yi 6, Kwang-Woong Lee 6, Kyung-Suk Suh 6, Won Kim 7, Woojin Kim 8, Hyunsoo Kim 8,9, Yoon Jun Kim 3, Jung-Hwan Yoon 3, Su Jong Yu 3* and Young-Joon Kim 1,4*
1Interdisciplinary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul, Republic of Korea
2R&D center, LepiDyne Inc, Seoul, Republic of Korea
3Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
4Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea
5Department of Integrative Bioscience & Biotechnology, College of Life Sciences, Sejong University, Seoul, Republic of Korea
6Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
7Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Republic of Korea
8Department of Bio-AI convergence, Chungnam National University, Daejeon, Republic of Korea
9Department of Convergent Bioscience and Informatics, Chungnam National University, Daejeon, Republic of Korea
†Si-Cho Kim, Da-Won Kim and Eun Ju Cho have contributed equally to this work.
*Corresponding authors: correspondence to Su Jong Yu or Young-Joon Kim
Abstract
To address the shortcomings of current hepatocellular carcinoma (HCC) surveillance tests, we set out to find HCC-specific methylation markers and develop a highly sensitive polymerase chain reaction (PCR)-based method to detect them in circulating cell-free DNA (cfDNA). The analysis of large methylome data revealed that Ring Finger Protein 135 (RNF135) and Lactate Dehydrogenase B (LDHB) are universally applicable HCC methylation markers with no discernible methylation level detected in any other tissue types. These markers were used to develop Methylation Sensitive High-Resolution Analysis (MS-HRM), and their diagnostic accuracy was tested using cfDNA from healthy, at-risk, and HCC patients. The combined MS-HRM RNF135 and LDHB analysis detected 57% of HCC, outperforming the alpha-fetoprotein (AFP) test's sensitivity of 45% at comparable specificity. Furthermore, when used with the AFP test, the methylation assay can detect 70% of HCC. Our findings suggest that the cfDNA methylation assay could be used for HCC liquid biopsy.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기